Protagonist Therapeutics Inc (PTGX) - Net Assets
Based on the latest financial reports, Protagonist Therapeutics Inc (PTGX) has net assets worth $645.44 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($701.69 Million) and total liabilities ($56.25 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Protagonist Therapeutics Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $645.44 Million |
| % of Total Assets | 91.98% |
| Annual Growth Rate | 55.9% |
| 5-Year Change | 141.52% |
| 10-Year Change | 6937.26% |
| Growth Volatility | 242.94 |
Protagonist Therapeutics Inc - Net Assets Trend (2014–2024)
This chart illustrates how Protagonist Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore how large is Protagonist Therapeutics Inc's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Protagonist Therapeutics Inc (2014–2024)
The table below shows the annual net assets of Protagonist Therapeutics Inc from 2014 to 2024. For live valuation and market cap data, see how much is Protagonist Therapeutics Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $675.29 Million | +100.58% |
| 2023-12-31 | $336.68 Million | +56.15% |
| 2022-12-31 | $215.61 Million | -28.14% |
| 2021-12-31 | $300.02 Million | +7.30% |
| 2020-12-31 | $279.61 Million | +249.66% |
| 2019-12-31 | $79.96 Million | -28.93% |
| 2018-12-31 | $112.52 Million | -6.73% |
| 2017-12-31 | $120.63 Million | +37.78% |
| 2016-12-31 | $87.56 Million | +812.41% |
| 2015-12-31 | $9.60 Million | +20.63% |
| 2014-12-31 | $7.96 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Protagonist Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 32796400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Comprehensive Income | $-82.00K | -0.01% |
| Other Components | $1.02 Billion | 150.44% |
| Total Equity | $675.29 Million | 100.00% |
Protagonist Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Protagonist Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
OHB SE
XETRA:OHB
|
$5.09 Billion |
|
ShenZhen YUTO Packaging Technology Co Ltd
SHE:002831
|
$5.10 Billion |
|
Lagercrantz Group AB (publ)
ST:LAGR-B
|
$5.10 Billion |
|
ServiceTitan, Inc. Class A Common Stock
NASDAQ:TTAN
|
$5.10 Billion |
|
Imeik Technology Development Co
SHE:300896
|
$5.09 Billion |
|
Big Shopping Centers Ltd
TA:BIG
|
$5.09 Billion |
|
COSCO SHIPPING Holdings Co. Ltd
F:C6G
|
$5.09 Billion |
|
Macy’s Inc
NYSE:M
|
$5.09 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Protagonist Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 336,677,000 to 675,295,000, a change of 338,618,000 (100.6%).
- Net income of 275,188,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 23,000.
- Other factors increased equity by 63,407,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $275.19 Million | +40.75% |
| Other Comprehensive Income | $23.00K | +0.0% |
| Other Changes | $63.41 Million | +9.39% |
| Total Change | $- | 100.58% |
Book Value vs Market Value Analysis
This analysis compares Protagonist Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.48x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 72.77x to 9.48x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $1.35 | $98.37 | x |
| 2015-12-31 | $1.63 | $98.37 | x |
| 2016-12-31 | $-9.93 | $98.37 | x |
| 2017-12-31 | $-5.74 | $98.37 | x |
| 2018-12-31 | $-6.28 | $98.37 | x |
| 2019-12-31 | $3.09 | $98.37 | x |
| 2020-12-31 | $8.13 | $98.37 | x |
| 2021-12-31 | $6.48 | $98.37 | x |
| 2022-12-31 | $4.40 | $98.37 | x |
| 2023-12-31 | $5.93 | $98.37 | x |
| 2024-12-31 | $10.38 | $98.37 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Protagonist Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 40.75%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 63.34%
- • Asset Turnover: 0.58x
- • Equity Multiplier: 1.10x
- Recent ROE (40.75%) is above the historical average (-45.09%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -139.18% | 0.00% | 0.00x | 1.30x | $-11.87 Million |
| 2015 | -154.84% | 0.00% | 0.00x | 1.55x | $-15.82 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-30.72 Million |
| 2017 | 0.00% | -184.20% | 0.12x | 0.00x | $-26.80 Million |
| 2018 | 0.00% | -125.87% | 0.22x | 0.00x | $-24.88 Million |
| 2019 | -96.53% | -33414.29% | 0.00x | 1.94x | $-85.18 Million |
| 2020 | -23.66% | -231.07% | 0.09x | 1.16x | $-94.11 Million |
| 2021 | -41.85% | -458.94% | 0.08x | 1.16x | $-155.55 Million |
| 2022 | -57.24% | -464.29% | 0.11x | 1.15x | $-144.97 Million |
| 2023 | -23.45% | -131.59% | 0.17x | 1.06x | $-112.62 Million |
| 2024 | 40.75% | 63.34% | 0.58x | 1.10x | $207.66 Million |
Industry Comparison
This section compares Protagonist Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Protagonist Therapeutics Inc (PTGX) | $645.44 Million | -139.18% | 0.09x | $5.09 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical tri… Read more